Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALGS Stock Forecast 2026-2027
$6.68
Current Price
$41.33M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALGS Price Targets
+2,519.8%
To High Target of $175.00
+618.6%
To Median Target of $48.00
+199.4%
To Low Target of $20.00
ALGS Price Momentum
-16.4%
1 Week Change
-9.0%
1 Month Change
+42.7%
1 Year Change
-28.3%
Year-to-Date Change
-51.2%
From 52W High of $13.69
+59.0%
From 52W Low of $4.20
📊 TOP ANALYST CALLS
Did ALGS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aligos is one of their latest high-conviction picks.
Latest ALGS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ALGS has a bullish consensus with a median price target of $48.00 (ranging from $20.00 to $175.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.68, the median forecast implies a 618.6% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Michael Yee at UBS, suggesting a 199.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALGS Analyst Ratings
5
Buy
0
Hold
0
Sell
ALGS Price Target Range
Low
$20.00
Average
$48.00
High
$175.00
Current: $6.68
Latest ALGS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALGS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | WestPark Capital | Buy | Initiates | $48.00 | |
| Mar 19, 2026 | Jefferies | Anthea Li | Buy | Assumes | $48.00 |
| Mar 11, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Initiates | $20.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Aug 18, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Assumes | $50.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $70.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $70.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Initiates | $75.00 |
| Jan 17, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $7.00 |
| Jan 6, 2023 | Jefferies | Michael Yee | Buy | Upgrade | $3.00 |
| Jan 6, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Upgrade | $3.00 |
| Nov 3, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Maintains | $2.00 |
| May 5, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Downgrade | $3.00 |
| Mar 23, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $7.00 |
| Mar 23, 2022 | Piper Sandler | Yasmeen Rahimi | Neutral | Downgrade | $4.00 |
| Mar 11, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $11.00 |
Aligos Therapeutics Inc. (ALGS) Competitors
The following stocks are similar to Aligos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aligos Therapeutics Inc. (ALGS) Financial Data
Valuation Metrics
Market Cap
$41.33M
Enterprise Value
$-31,259,450
P/E Ratio
N/A
PEG Ratio
-1.3x
Price/Sales
18.9x
Growth & Margins
Revenue Growth (YoY)
-73.1%
Gross Margin
N/A
Operating Margin
-12,907.7%
Net Margin
0.0%
EPS Growth
-73.1%
Financial Health
Cash/Price Ratio
+188.3%
Current Ratio
3.9x
Debt/Equity
9.8x
ROE
-196.9%
ROA
-69.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aligos Therapeutics Inc. (ALGS) Business Model
About Aligos Therapeutics Inc.
What They Do
Develops small molecule therapeutics for liver diseases.
Business Model
Aligos Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through partnerships and collaborations with larger pharmaceutical companies and research institutions. It focuses on advancing its innovative drug pipeline, which includes therapies for chronic hepatitis B, MASH, and COVID-19, often leveraging licensing agreements to monetize its research and development efforts.
Additional Information
Founded in 2018 and based in South San Francisco, Aligos Therapeutics collaborates with notable partners such as Merck and Emory University to enhance its research capabilities and commercial potential in targeted therapies for viral infections and liver diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Country
United States
IPO Year
2020
Website
www.aligos.comAligos Therapeutics Inc. (ALGS) Latest News & Analysis
Latest News
Quick Summary
An agreement has been reached to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China, potentially strengthening its market position.
Why It Matters
The agreement boosts potential market share for pevifoscorvir sodium in Greater China, indicating growth opportunities and increased revenue potential for involved companies.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Aligos Therapeutics has signed an exclusive licensing deal with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic HBV in Greater China.
Why It Matters
Aligos Therapeutics’ exclusive licensing agreement with Amoytop expands its market reach in Greater China for a key HBV treatment, potentially boosting revenue and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics announced positive interim results from its Phase 2 study of pevifoscorvir sodium for chronic HBV, with FDA granting Fast Track Designation for the drug.
Why It Matters
Positive interim results and FDA Fast Track Designation for Aligos' drug could enhance its market potential, driving investor interest and potentially increasing stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
1 month ago
Quick Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) reported its business progress and financial results for Q4 and full year 2025, focusing on therapies for liver and viral diseases.
Why It Matters
Aligos Therapeutics' financial results and business progress indicate its growth potential and innovation in the biotech sector, impacting stock performance and investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics (Nasdaq: ALGS) will report Q4 2025 financial results on March 5, 2026, before U.S. markets open.
Why It Matters
Aligos Therapeutics' upcoming financial results may impact its stock price and investor sentiment, reflecting its performance and future prospects in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics (Nasdaq: ALGS) reported positive data from two presentations at the CROI conference, focused on therapies for liver and viral diseases.
Why It Matters
Positive data from Aligos Therapeutics at a major conference can boost investor confidence, potentially leading to stock price increases and heightened interest in the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ALGS Stock
What is Aligos Therapeutics Inc.'s (ALGS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Aligos Therapeutics Inc. (ALGS) has a median price target of $48.00. The highest price target is $175.00 and the lowest is $20.00.
Is ALGS stock a good investment in 2026?
According to current analyst ratings, ALGS has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALGS stock?
Wall Street analysts predict ALGS stock could reach $48.00 in the next 12 months. This represents a 618.6% increase from the current price of $6.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aligos Therapeutics Inc.'s business model?
Aligos Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through partnerships and collaborations with larger pharmaceutical companies and research institutions. It focuses on advancing its innovative drug pipeline, which includes therapies for chronic hepatitis B, MASH, and COVID-19, often leveraging licensing agreements to monetize its research and development efforts.
What is the highest forecasted price for ALGS Aligos Therapeutics Inc.?
The highest price target for ALGS is $175.00 from at , which represents a 2,519.8% increase from the current price of $6.68.
What is the lowest forecasted price for ALGS Aligos Therapeutics Inc.?
The lowest price target for ALGS is $20.00 from Michael Yee at UBS, which represents a 199.4% increase from the current price of $6.68.
What is the overall ALGS consensus from analysts for Aligos Therapeutics Inc.?
The overall analyst consensus for ALGS is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $48.00.
How accurate are ALGS stock price projections?
Stock price projections, including those for Aligos Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 1:55 PM UTC